Beckton Dickinson – BD is investing over $35mn in order to expand production of the prefilled flush syringes in the US at its facility in Columbus, Nebraska, the company confirmed on August 4, 2025.
Apparently, this investment is going to add almost 50 jobs at the site and equip BD in order to make hundreds of millions more units a year in order to meet the rising demand coming from US hospitals as well as health systems.
BD has gone on to frame this spending as part of its ongoing commitment to its Posiflush line, which has also witnessed it invest over $80mn in order to expand the production of syringes in the last three years.
Healthcare professionals make use of flush syringes in order to stop vascular access systems from getting blocked and to enable removing medication that is left at the catheter site. The resilience of the supply chain of the industry came under scrutiny when, in 2021, Cardinal Health recalled Monoject devices, leading to a shortage that persisted till 2023 and drove the FDA to share strategies so as to conserve these devices.
Due to this backdrop, BD has already increased its US Posiflush production capacity. The company said that it has grown capacity by almost 10% in 2025 by bringing its total output of the prefilled flush syringes in the US to be more than 750 million units.
In 2024, BD added new needle and syringe production lines at its plant in Nebraska and Connecticut, which were a part of over a $10mn investment. The latest investment comes three months after BD remarked that it was going to invest $2.5bn in US manufacturing in the next five years.
It is well to be noted that this week’s $35mn commitment happens to be a part of a series of vows by companies to invest in manufacturing within the US, due to the growing threat and imposition of tariffs. Yet BD has also warned that tariffs are actually causing it to relocate some of its production lines from Nebraska to overseas facilities.
The CEO of BD, Tom Polen, has explained how tariffs are moving some of its production out of the US at an event that was hosted by Golden Sachs in June this year.
Pollen had said that historically, their flush syringes always came out of Columbus, Nebraska, and then they would ship those to China. They have a facility in China now that is going to source just for China. He added that there is indeed more downside to tariff impacts from a US manufacturing perspective when it comes to the medtech industry as compared to others.
